modernretina.com

Website beoordeling modernretina.com

Modern Retina – Ophthalmology News, Events & Expert Insights

 Gegenereerd op Maart 31 2026 15:12 PM

Oude statistieken? UPDATE !

De score is 57/100

SEO Content

Title

Modern Retina – Ophthalmology News, Events & Expert Insights

Lengte : 60

Perfect, uw title tag bevat tussen de 10 en 70 karakters.

Description

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Lengte : 155

Perfect, uw meta description bevat tussen de 70 en 160 karakters.

Keywords

Erg slecht. We hebben geen meta keywords gevonden in uw website. Gebruik deze gratis online meta tags generator om keywords te genereren.

Og Meta Properties

Goed, uw page maakt gebruik van Og Properties.

Property Content
title Modern Retina
type website
image https://www.modernretina.com/MR_Hover_Logo.jpg
url https://www.modernretina.com/
image:url https://www.modernretina.com/MR_Hover_Logo.jpg
image:width 1200
image:height 630
image:alt Modern Retina – Ophthalmology News, Events & Expert Insights

Headings

H1 H2 H3 H4 H5 H6
1 56 46 4 16 0
  • [H1] Latest News
  • [H2] Conference Coverage
  • [H2] Trending on Modern Retina
  • [H2] Shorts
  • [H2] Podcasts
  • [H2] Videos
  • [H2] Modern Retina Digital Edition
  • [H2] Continuing Medical Education
  • [H2] (CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] (COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] (CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] Practical Approaches to Modern Dry Eye Treatment and Management
  • [H2] (COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] 20th Annual Controversies in Modern Eye Care
  • [H2] (CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] (COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Collaborative Care Symposium
  • [H2] Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
  • [H2] (CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] (COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop
  • [H2] (COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] (CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] Interventional Dry Eye: A Stepwise Treatment & Management Approach
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] (CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management
  • [H2] (CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment
  • [H2] (CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice
  • [H2] (CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP
  • [H2] All News
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS
  • [H3] The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD
  • [H3] Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME
  • [H3] The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD
  • [H3] PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice
  • [H3] PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice
  • [H3] Integrating AI to manage DR in a primary care setting
  • [H3] What to expect from virtual AAO 2020
  • [H3] Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion
  • [H3] Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
  • [H3] Ophthalmic drug shortages more frequent, longer lasting than average
  • [H3] Johnson & Johnson’s TECNIS PureSee EDOF IOL cleared for US market
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] NovaBridge, Visara report positive phase 2a results for dual VEGF-A/ANG-2 inhibitor VIS-101
  • [H3] FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
  • [H3] Ocugen completes enrollment in liMeliGhT phase 3 trial of OCU400 for retinitis pigmentosa
  • [H3] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H3] Q&A: AI-predicted retinal function shows promise in geographic atrophy
  • [H3] Dr. Mali’s top 5 predictions in ophthalmology for 2026
  • [H3] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H3] Q&A: Gennady Landa, MD, shares clinical insights on the ranibizumab ocular implant
  • [H3] Samsung Bioepis reaches settlement agreement for Eylea (aflibercept) biosimilar
  • [H3] ISS 2026 highlights advances in ophthalmic imaging for retinal practice
  • [H3] American College of Physicians policy paper urges medical community to drop the term “'provider"
  • [H3] PRIMA System: A major step in the battle against GA
  • [H3] MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
  • [H3] Metformin use associated with reduced incidence of intermediate AMD
  • [H3] FDA decision: Carbachol–brimonidine ophthalmic solution approved for presbyopia following BRIO phase 3 results
  • [H3] New optoretinography technique allows direct measurement of rod function in vivo
  • [H3] Navigating geographic atrophy from biomarkers to bilateral therapy
  • [H3] Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Long-lived Greenland sharks may point to new approaches for retinal disease
  • [H3] Molecular insights and clinical experience: Extending anti-VEGF durability
  • [H3] Q&A: Evolving approaches to geographic atrophy management
  • [H3] Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
  • [H3] Rates of retinal layer thinning predict visual field progression in glaucoma
  • [H3] First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
  • [H3] FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
  • [H3] 8 things to know about aflibercept 8 mg for retinal vascular disease
  • [H3] A new treatment round-up for AMD and GA
  • [H4] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H4] Phase 2 topline data: Ocugen OCU410 reduces geographic atrophy lesion growth by 31% at 12 months
  • [H4] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H4] ONL Therapeutics randomizes first European patient in phase 2 GA trial of Xelafaslatide
  • [H5] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H5] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H5] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H5] Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline
  • [H5] The Retina TL;DR with Dr. Weng: Targeting the Fas signaling pathway with David Zacks, MD, PhD
  • [H5] Evaluating Safety and Clinical Confidence between Aflibercept 8 mg and 2 mg in Retinal Vascular Diseases
  • [H5] Management Approaches for Suboptimal Responders in AMD, DME, and RVO
  • [H5] Comparing Aflibercept 8 mg and Faricimab in RVO
  • [H5] Insights from Privotal Trials for Aflibercept (8 mg) in RVO
  • [H5] Evaluating Retinal Drying, Durability and IOP Management with Second-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
  • [H5] Loading Dose Adjustments and Treatment Switching Strategies in Retinal Vascular Diseases
  • [H5] Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
  • [H5] Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal Vascular Diseases
  • [H5] Clinical Insights Shaping Real-World Decision-Making in Geographic Atrophy
  • [H5] Managing Geographic Atrophy in a 90-Year-Old Patient with Coexisting Neovascular AMD and Recurrent CNV Activation
  • [H5] Evaluating Progressive Multifocal Geographic Atrophy in an Asymptomatic 81-Year-Old Male

Afbeeldingen

We vonden 135 afbeeldingen in de pagina.

23 alt attributen ontbreken. Voeg alternatieve text toe zodat zoekmachines beter kunnen beoordelen wat het onderwerp van de afbeeldingen is.

Text/HTML Ratio

Ratio : 3%

De ratio van text tot HTML code is below 15 procent, dit betekent dat uw pagina waarschijnlijk meer tekst nodig heeft.

Flash

Perfect, geen Flash content gevonden in uw website.

Iframe

Perfect, er zijn geen Iframes in uw website aangetroffen.

Herschreven URL

Perfect. Uw links zien er vriendelijk uit!

Underscores in de URLs

Perfect! Geen underscores gevonden in uw URLs.

In-page links

We vonden een totaal van 89 links inclusie 0 link(s) naar bestanden

Ankertekst Type samenstelling
All News Intern doFollow
Blogs Intern doFollow
All Videos Intern doFollow
Case-Based Roundtable Series Intern doFollow
Eichenbaum Acorns Intern doFollow
Expert Interviews Intern doFollow
Eyeviews Intern doFollow
Insights Intern doFollow
Medical World News Extern doFollow
Podcasts Intern doFollow
Rapid Readouts Intern doFollow
The Retina TL;DR Intern doFollow
Viewpoints Intern doFollow
Conference Coverage Intern doFollow
Conference Listing Intern doFollow
Modern Retina Digital Edition Intern doFollow
Supplements And Featured Publications Intern doFollow
Between the Lines Intern doFollow
CME/CE Intern doFollow
EYLEA 8mg for nAMD and DME Treatment Intern doFollow
Sponsored Resources Intern doFollow
Partners Intern doFollow
Subscribe Intern doFollow
AMD Intern doFollow
Wet AMD Intern doFollow
Biosimilar Intern doFollow
Diabetic Macular Edema Intern doFollow
Diabetic Eye Awareness Intern doFollow
Diabetic Retinopathy Intern doFollow
Geographic Atrophy Intern doFollow
Imaging Intern doFollow
Inherited Retinal Diseases Intern doFollow
Ophthalmology Intern doFollow
RVO Intern doFollow
Retina Technology Intern doFollow
Retinal Surgery Intern doFollow
Uveitis Intern doFollow
Geographic Atrophy Intern doFollow
ISS 2026 highlights advances in ophthalmic imaging for retinal practice Intern doFollow
FLORetina: Inadvertent anti-VEGF interval increases during the COVID-19 pandemic Intern doFollow
Treating MacTel: First identify patient candidates and appropriate eye selection Intern doFollow
A medical fellow finds some magic at the AAO Annual Meeting Intern doFollow
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight Intern doFollow
FLORetina 2025: Updates on tinlarebant in adolescent Stargardt disease Intern doFollow
FLORetina 2025: Long-term follow-up in pediatric gene therapy Intern doFollow
FLORetina 2025: Mary Elizabeth Hartnett on ROP research and risk management Intern doFollow
FLORetina 2025: Reframing retinal disease through the lens of choroidal health Intern doFollow
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage Intern doFollow
Martin David Harp Intern doFollow
Christina Y. Weng, MD, MBA, FASRS Intern doFollow
View All Intern doFollow
Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO Intern doFollow
Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast Intern doFollow
Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS Intern doFollow
The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD Intern doFollow
Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME Intern doFollow
The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD Intern doFollow
PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice Intern doFollow
PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice Intern doFollow
Integrating AI to manage DR in a primary care setting Intern doFollow
What to expect from virtual AAO 2020 Intern doFollow
View More Intern doFollow
Navigating geographic atrophy from biomarkers to bilateral therapy Intern doFollow
8 things to know about aflibercept 8 mg for retinal vascular disease Intern doFollow
Inside the mindset of an early adopter Intern doFollow
Challenges for young physicians treating patients with GA Intern doFollow
AAO highlight: Looking ahead to 2026 Intern doFollow
How AI is reshaping ophthalmology in 2025 and beyond Intern doFollow
Seeing the difference: Multimodal imaging for AMD and GA Intern doFollow
Ryan Livingston Intern doFollow
Lynda Charters Intern doFollow
Kevin Kunzmann Intern doFollow
Jeffry D. Gerson, OD, FAAO Intern doFollow
Theodore Leng, MD, MS Intern doFollow
Sheryl Stevenson Intern doFollow
Joshua Mali, MD Intern doFollow
Arshad M. Khanani, MD, MA, FASRS Intern doFollow
Modern Retina Staff Reports Intern doFollow
Jayanth Sridhar, MD Intern doFollow
Matt Hoffman Intern doFollow
Sheila Setork, OD Intern doFollow
About Intern doFollow
Advertise Intern doFollow
Editorial Intern doFollow
Contact Us Intern doFollow
Terms and Conditions Intern doFollow
Privacy Intern doFollow
Do Not Sell My Personal Information Extern doFollow
Home Intern doFollow

SEO Keywords

Keywords Cloud

fasrs management cme more view cope video track faao retinal

Keywords Consistentie

Keyword Content Title Keywords Description Headings
more 64
view 52
video 44
track 35
faao 24

Bruikbaarheid

Url

Domein : modernretina.com

Lengte : 16

Favicon

Goed, uw website heeft een favicon.

Printbaarheid

Jammer. We vonden geen Print-Vriendelijke CSS.

Taal

Goed. Uw ingestelde taal is en.

Dublin Core

Deze pagina maakt geen gebruik van Dublin Core.

Document

Doctype

HTML 5

Encoding

Perfect. Uw ingestelde Charset is UTF-8.

W3C Validiteit

Fouten : 0

Waarschuwingen : 0

E-mail Privacy

Waarschuwing! Er is op zijn minst 1 e-mailadres gevonden als platte tekst. (voorkom spam!). Gebruik deze gratis antispam protector om e-mailadressen te verbergen voor spammers.

Niet ondersteunde HTML

Geweldig! We hebben geen niet meer ondersteunde HTMl tags gevonden in uw HTML.

Speed Tips

Geweldig, uw website heeft geen tabellen in een tabel.
Jammer, uw website maakt gebruik van inline styles.
Geweldig, uw website heeft een correct aantal CSS bestanden.
Jammer, uw website heeft teveel JS bestanden (meer dan 6).
Perfect, uw website haalt voordeel uit gzip.

Mobile

Mobile Optimization

Apple Icon
Meta Viewport Tag
Flash content

Optimalisatie

XML Sitemap

Geweldig, uw website heeft een XML sitemap.

https://www.modernretina.com/sitemap.xml
https://www.modernretina.com/sitemap-news.xml

Robots.txt

https://modernretina.com/robots.txt

Geweldig uw website heeft een robots.txt bestand.

Analytics

Perfect, uw website heeft een analytics tool.

   Google Analytics

PageSpeed Insights

Device
Categorieën

Free SEO Testing Tool

Website review is een gratis tool waarmee u eenvoudig uw website kunt analyseren